Literature DB >> 15530637

Neuroprotection by tetracyclines.

María Domercq1, Carlos Matute.   

Abstract

The neuroprotective properties of tetracyclines have been clearly established in rodent models of acute and chronic neurodegeneration during the past few years. Recent findings have provided novel insights into the molecular and cellular mechanisms of protection of neurons and oligodendrocytes by tetracyclines. These advances have prompted several clinical trials with minocycline, the most effective tetracycline, which are still in their early phases. Thus, tetracyclines hold great promise as therapeutic agents for the treatment of human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15530637     DOI: 10.1016/j.tips.2004.10.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  50 in total

1.  Minocycline improves functional outcomes, memory deficits, and histopathology after endovascular perforation-induced subarachnoid hemorrhage in rats.

Authors:  Prativa Sherchan; Tim Lekic; Hidenori Suzuki; Yu Hasegawa; William Rolland; Kamil Duris; Yan Zhan; Jiping Tang; John H Zhang
Journal:  J Neurotrauma       Date:  2011-10-20       Impact factor: 5.269

2.  Lipopolysaccharide-Induced Apoptosis of Astrocytes: Therapeutic Intervention by Minocycline.

Authors:  Arpita Sharma; Nisha Patro; Ishan K Patro
Journal:  Cell Mol Neurobiol       Date:  2015-07-19       Impact factor: 5.046

3.  Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury.

Authors:  Matthew L Kelso; Nicole N Scheff; Stephen W Scheff; James R Pauly
Journal:  Neurosci Lett       Date:  2010-11-05       Impact factor: 3.046

4.  Early-Life Social Isolation-Induced Depressive-Like Behavior in Rats Results in Microglial Activation and Neuronal Histone Methylation that Are Mitigated by Minocycline.

Authors:  Hong-Tao Wang; Fu-Lian Huang; Zhao-Lan Hu; Wen-Juan Zhang; Xiao-Qing Qiao; Yan-Qing Huang; Ru-Ping Dai; Fang Li; Chang-Qi Li
Journal:  Neurotox Res       Date:  2017-01-16       Impact factor: 3.911

Review 5.  Emerging Concepts in the Treatment of Diabetic Retinopathy.

Authors:  Michael Patrick Ellis; Daniella Lent-Schochet; Therlinder Lo; Glenn Yiu
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810

6.  Novel modulators of poly(ADP-ribose) polymerase.

Authors:  Csaba Szabo; Pal Pacher; Raymond A Swanson
Journal:  Trends Pharmacol Sci       Date:  2006-10-19       Impact factor: 14.819

Review 7.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways.

Authors:  Flávia V Santa-Cecília; Benjamin Socias; Mohand O Ouidja; Julia E Sepulveda-Diaz; Leonardo Acuña; Rangel L Silva; Patrick P Michel; Elaine Del-Bel; Thiago M Cunha; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2016-01-08       Impact factor: 3.911

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.